2023
HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience
Podany P, Golastani R, Zhan H, Liang Y, Harigopal M, Krishnamurti U. HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience. American Journal Of Clinical Pathology 2023, 160: s9-s10. DOI: 10.1093/ajcp/aqad150.021.Peer-Reviewed Original ResearchLow HER2 expressionInvasive breast carcinomaIHC scoreHER2 expressionGroup 1Group 3HER2 immunohistochemistryHER2 testingGroup 2HER2 FISHGroup 4ASCO/CAP guidelinesGroup 5Single institutional experienceRecent clinical trialsStandard of careASCO/CAP 2018 guidelinesHER2/CEP17 ratioEquivocal HER2HER2 positivityTrastuzumab deruxtecanMore patientsCAP guidelinesPatient eligibilityCase report
2017
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin W, Yergiyev O, Bunker M, Silverman J, Krishnamurti U. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2017, 25: 553-558. PMID: 26945445, DOI: 10.1097/pai.0000000000000349.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaHER2 amplificationHER2 overexpressionER negativityPathologic stageHistologic gradeP53 positivityGRB7 expressionBreast cancerBreast carcinomaInvasive breast cancer correlatesInvasive breast cancerBreast cancer correlatesChromosome 17 copy numberAntiestrogen therapyPR expressionPredictive factorsHER2 expressionCancer correlatesPR testingP53 immunohistochemistryAggressive phenotypeHER2 geneHER2P53 status